AMAG

AMAG Pharmaceuticals, Inc. News Headlines

$20.71
*  
0.31
1.52%
Get AMAG Alerts
*Delayed - data as of Aug. 22, 2014  -  Find a broker to begin trading AMAG now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
7/30/2014 1:50:00 PM - Zacks.com

Sector Update: Health Care Stocks Hang On for Small Gains; AMAG Pharma Climbs After Topping Analyst Expectations
7/29/2014 4:00:24 PM - MT Newswires

Sector Update: Health Care
7/29/2014 3:59:21 PM - MT Newswires

Why AMAG Pharmaceuticals (AMAG) Could Be Positioned for a Slump - Tale of the Tape
7/28/2014 8:46:00 AM - Zacks.com

Zacks Rank #5 Additions for Monday - Tale of the Tape
7/21/2014 9:30:00 AM - Zacks.com

AMAG Pharma (AMAG) is in Overbought Territory: What's Next? - Tale of the Tape
7/2/2014 9:46:55 AM - Zacks.com

Zacks Rank #5 Additions for Tuesday - Tale of the Tape
6/24/2014 9:30:00 AM - Zacks.com

AMAG Pharma: USPTO Extends Patent Term For Ferumoxytol By 1,209 Days
6/6/2014 8:22:00 AM - RTT News

AMAG Pharmaceuticals: Biotech At A Turning Point
5/5/2014 10:51:00 AM - Seeking Alpha

Wider-than-Expected Q1 Loss at AMAG - Analyst Blog
4/25/2014 11:00:01 AM - Zacks.com

Wider-than-Expected Q4 Loss at AMAG - Analyst Blog
2/7/2014 11:40:01 AM - Zacks.com

AMAG Slides on Regulatory Setback - Analyst Blog
1/23/2014 7:40:01 PM - Zacks.com

AMAG's Feraheme Revs Look Good - Analyst Blog
1/14/2014 6:20:01 PM - Zacks.com

Update on AMAG's Feraheme - Analyst Blog
1/9/2014 2:00:01 PM - Zacks.com

MYGN Unveils Prolaris Study Results - Analyst Blog
12/5/2013 5:05:32 PM - Zacks.com

Oculus Gains on Scar Product Approval - Analyst Blog
12/5/2013 5:04:54 PM - Zacks.com

BioMarin Seeks Canadian Approval - Analyst Blog
12/5/2013 12:50:01 PM - Zacks.com

Positive Data on ChemoCentryx Candidate - Analyst Blog
12/5/2013 12:05:33 PM - Zacks.com

AMBI Plunges on Disappointing FDA News - Analyst Blog
12/5/2013 12:05:21 PM - Zacks.com

Cytokinetics Progresses with Tirasemtiv - Analyst Blog
12/5/2013 8:06:01 AM - Zacks.com

Affymetrix Remains Outperform - Analyst Blog
12/4/2013 3:40:01 PM - Zacks.com

MYGN Battles Odds, Shares Fall - Analyst Blog
12/4/2013 2:05:07 PM - Zacks.com

Zacks #1 Rank Additions for Wednesday - Tale of the Tape
12/4/2013 9:53:53 AM - Zacks.com

FDA Agrees to BDSI's Phase III Program - Analyst Blog
12/3/2013 11:53:56 AM - Zacks.com

Orphan Drug Status for CNAT's Emricasan - Analyst Blog
12/3/2013 11:53:34 AM - Zacks.com